References
Domecq C, Naranjo CA, Ruiz I, et al. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980; 18: 362–6
Department of Health and Human Services. New drug and antibiotic regulations: section 314.80, post marketing reporting of adverse drug experiences. Fed Regist 1985; 50(30): 7500–1
Naranjo CA, Ruiz I, Busto U, et al. Drug surveillance of hospitalized patients: the University of Chile experience. Abstracts of the 7th International Congress on Pharmacology; 1978: Paris. England: Pergamon Press, 1978: 949
Briefings on JCAHO (Joint Commission on the Accreditation of Healthcare Organizations) 1991; 2 (5): 1-3
Classen DC, Pestotnik SL, Evans S, et al. Computerized surveillance of adverse drug events in hospitalized patients. JAMA 1991; 266: 2847–51
Caranasos GJ, Stewart RB, Cluff LE. Drug-induced illness leading to hospitalization. JAMA 1974; 228: 713–7
Miller RR. Hospital admissions due to adverse drug reactions: a report from the Boston Collaborative Drug Surveillance Program. Arch Intern Med 1974; 134: 219–3
Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991; 324: 377–84
Philips MS. Qualiy assurance through adverse drug reaction reporting: improving hypnotic prescribing. Hosp Pharm 1990; 25: 246–8
Hurwitz N. Prediposing factors in adverse reactions to drugs. Br Med J 1969; 1: 536–9
Klein L, Klein M, Sturm H, et al. The frequency of adverse drug reactions as dependent upon age, sex and duration of hospitalization. Int J Clin Pharmacol 1976; 13: 187–95
Botiger LE. Adverse drug reactions: an analysis of 310 consecutive reports to the Swedish drug reaction committee. J Clin Pharmacol 1973; 13: 373–82
Vakil BJ, Kuklarni RD, Chabria NL, et al. Intense surveillance of adverse drug reactions. J Clin Pharmacol 1987; 15: 435–41
Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharm 1984; 4: 270–8
Simpson JM, Bateman DN, Rawlins MD. Using the adverse reactions register to study the effects of age and sex on adverse drug reactions. Stat Med 1987; 6: 863–7
Braude MC. Drugs and drug interactions in the elderly woman. In: Ray BA, Braude MC, editors. Women and drugs: a new era for research. NIDA Research Monograph 65. Rockville: Department of Health and Human Services, 1986: 58–64
Hamilton JA, Yonkers KA. Sex differences in pharmacokinetics of psychotropic medications. Part 1: Physiological basis for effects. In: Jensvold MJ, Halbreich U, Hamilton JA, editors. Psychopharmacology of women: sex, gender and hormonal considerations. 1st ed., Vol. 1. Washington, DC: American Psychiatric Press, 1995
Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981; 80: 1497–1500
Horowitz M, Maddern GJ, Chatterton BE. The normal menstrual cycle has no effect on gastric emptying. Br J Obstet Gynecol 1985; 92: 743–74
Datz FLI, Christian PE, Moore J. Gender-related differences in gastric emptying. Nucl Med 1987; 28: 384–91
Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587–95
Gur RC, Gur RE, Obrist WD, et al. Sex and handedness differences in crebral blood flow during rest and cognitive activity. Science 1982; 217: 659–61
Riester EF, Pantuck EJ, Pantuck CB, et al. Antipyrine metabolism during the menstrual cycle. Clin Pharmacol Ther 1980; 28: 384–91
Fraser HS, Macklaw JL, Bulpitt CJ, et al. Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther 1977; 22: 799–808
O’Malley K, Crooks J, Duke E, et al. Effect of age and sex on human drug metabolism. Br Med J 1971; 3: 607–9
Walle T, Walle UK, Cowart TD, et al. Pathway-selective sex diffrences in the metabolic clarance of propranolol in human subjects. Clin Phamacol Ther 1989; 46: 257–63
Frezza M, DiPadova C, Pozzato G, et al. High blood alcohol levels in women. N Engl J Med 1990; 322: 95–9
Ashley MJ, Olin JS, LeRiche WH, et al. Morbidity in alcoholics: evidence for accelerated development of physical disease in women. Arch Intern Med 1977; 137: 883–7
Jones BM, Jones MK. Alcohol effects in women during the menstrual cycle. Ann NY Acad Sci 1977: 576-87
Jochemsen R, Vander Graaf M, Boeijinga JK, et al. Influence of sex, menstrual cycle and oral contraceptives on the disposition of nitrazepam. Br J Clin Pharmacol 1982; 13: 319–24
Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depressions in women. Arch Gen Psychiatry 1979; 36: 550–4
Conrad CD, Hamilton JA. Recent premenstrual decline in lithium concentration: clinical correlates and treatment implications. J Am Acad Child Adolesc Psychiatry 1986; 26: 852–3
Kimmel S, Gonsalves L, Young D, et al. Fluctuating levels of antidepressants. J Psychosom Obstet Gynecol 1992: 13: 277–80
Stewart DE, Fairman M, Barbadoro S, et al. Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disroder. Biol Psychiatry 1994; 36: 201–2
Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull 1992; 18: 701–15
Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 1983; 24(2): 125–8
Hamilton J. Forging a women’s health resource agenda (conference proceedings). Clinical pharmacology panel report. In: Blumenthal SJ, Parry B, Sherwin B, editors. Washington, DC: National Women’s Health Resource Center, 1991: 1–27
Ellinwood EH, Easier ME, Linnoila M, et al. Effects of oral contraceptives on diazepam-induced psychomotor impairment. Clin Pharmacol Ther 1983; 35: 360–6
Kroboth PD, Smith RB, Stoehr GP, et al. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther 1985; 38: 525–32
Abernathy DR, Geenblatt DJ, Shader RI. Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984; 35(6): 792–7
Mishell DR. Contraception. N Engl J Med 1989; 320: 777–87
Allgulander C. Psychoactive drug use in a general population sample, Sweden: correlates with perceived health, psychiatric diagnoses, and mortality in an automated record-linkage study. Am J Public Health 1989; 79: 1006–9
Borda I, Jick H, Slone D, et al. Studies of drug usage in five Boston hospitals. JAMA 1967; 202: 170–4
Cooperstock R. Sex differences in the use of mood-modifying drugs: an explanatory model. J Health Soc Behav 1971; 12: 238–44
Hohmann AA. Gender bias in psychotropic drug prescribing in primary care. Med Care 1988; 27: 478–90
Svardstad BL, Clearly PD, Mechanic D, et al. Gender differences in the aquisition of prescribed drugs: an epidemiological study. Med Care 1987; 25: 1089–98
Ashton H. Psychotropic-drug prescribing for women. Br J Psychiatry 1991; 148: 30–5
Hopf G, Mathis B. Adverse reactions reporting and age. Lancet 1988; 2: 1079–80
Food and Drug Administration. General considerations for the clinical evaluation of drugs. Publication no. MEW (FDA) 77-3040. Washington, DC: Government Printing Office, 1977
Halbreich U, Carson SW. Drug studies in women of childbearing age: eithical and methodological considerations. J Clin Psychopharmacol 1989; 9: 328–33
Center for Drug Evaluation and Research. Guideline for the study of and evaluation of gender differences in the clinical evaluation of drugs. Publication no. 93D-0236. Washington, DC: Food and Drug Administration, 1994
Yonkers KA, Harrison W. The inclusion of women in psychopharmacologic trials. J Clin Psychopharm 1993; 13(6): 380–2
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kando, J.C., Yonkers, K.A. & Cole, J.O. Gender as a Risk Factor for Adverse Events to Medications. Drugs 50, 1–6 (1995). https://doi.org/10.2165/00003495-199550010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199550010-00001